NSD-IN-2
Based on 2 publication(s) in Google Scholar
NSD-IN-2 is a potent and irreversible NSD inhibitor with inhibitory activity towards members of the NSD family (NSD1/2/3). NSD-IN-2 can be used in research of acute myeloid leukemia.
For research use only. We do not sell to patients.
- Purity: 98.16%
- CAS No.: 2351225-46-0
- Formula: C10H11N3OS
- Molecular Weight:221.28
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) NSD-IN-2
MoreAll Histone Methyltransferase Isoforms
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Bone marrow cell | GI50 |
0.9 μM
Compound: 119
|
Anticancer activity against BALB/c mouse bone marrow cells expressing NUP98-NSD1 assessed as cell growth inhibition incubated for 7 days by MTT assay
Anticancer activity against BALB/c mouse bone marrow cells expressing NUP98-NSD1 assessed as cell growth inhibition incubated for 7 days by MTT assay
|
[PMID: 34591474] |
| PBMC | GI50 |
0.87 μM
Compound: 23; BT5
|
Anticancer activity against mouse PBMC cells harboring NUP98-NSD1 fusion protein assessed as cell growth inhibition measured after 7 days by MTT assay
Anticancer activity against mouse PBMC cells harboring NUP98-NSD1 fusion protein assessed as cell growth inhibition measured after 7 days by MTT assay
|
[PMID: 36528996] |
| PBMC | GI50 |
1.3 μM
Compound: 23; BT5
|
Anticancer activity against mouse PBMC cells harboring NUP98-NSD1 fusion protein assessed as cell growth inhibition measured after 3 days by MTT assay
Anticancer activity against mouse PBMC cells harboring NUP98-NSD1 fusion protein assessed as cell growth inhibition measured after 3 days by MTT assay
|
[PMID: 36528996] |
Chemical Information
-
CAS No. 2351225-46-0
-
Appearance Solid
-
Molecular Weight 221.28
-
Formula C10H11N3OS
-
Color White to light yellow
-
SMILES
OC1=C2N=C(N)SC2=CC(N3C(C)C3)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Cancer Res
NSD1-Mediated PPARγ Methylation Enhances PTEN Activity to Suppress Glycolysis and Tumor Progression in Endometrial Cancer. [Abstract]2026 Mar 2. PMID: 41770031 -
J Cell Commun Signal
Nuclear binding SET domain 1 alleviates cartilage ferroptosis in knee osteoarthritis by upregulating the krüppel-like factor 9/autophagy-related 14 pathway via H3K36me2 modification. [Abstract]2025 Jun 29;19(3):e70027. PMID: 40584820
Solvent & Solubility
DMSO : 100 mg/mL (451.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (22.60 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Tomasz C, et, al. Nsd family inhibitors and methods of treatment therewith. US20190183865A1.
[2]. Yang Q, et al. Nuclear binding SET domain 1 alleviates cartilage ferroptosis in knee osteoarthritis by upregulating the krüppel-like factor 9/autophagy-related 14 pathway via H3K36me2 modification. J Cell Commun Signal. 2025 Jun 29;19(3):e70027. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.5192 mL | 22.5958 mL | 45.1916 mL | 112.9790 mL |
| 5 mM | 0.9038 mL | 4.5192 mL | 9.0383 mL | 22.5958 mL | |
| 10 mM | 0.4519 mL | 2.2596 mL | 4.5192 mL | 11.2979 mL | |
| 15 mM | 0.3013 mL | 1.5064 mL | 3.0128 mL | 7.5319 mL | |
| 20 mM | 0.2260 mL | 1.1298 mL | 2.2596 mL | 5.6490 mL | |
| 25 mM | 0.1808 mL | 0.9038 mL | 1.8077 mL | 4.5192 mL | |
| 30 mM | 0.1506 mL | 0.7532 mL | 1.5064 mL | 3.7660 mL | |
| 40 mM | 0.1130 mL | 0.5649 mL | 1.1298 mL | 2.8245 mL | |
| 50 mM | 0.0904 mL | 0.4519 mL | 0.9038 mL | 2.2596 mL | |
| 60 mM | 0.0753 mL | 0.3766 mL | 0.7532 mL | 1.8830 mL | |
| 80 mM | 0.0565 mL | 0.2824 mL | 0.5649 mL | 1.4122 mL | |
| 100 mM | 0.0452 mL | 0.2260 mL | 0.4519 mL | 1.1298 mL |
Powered by Bioz